| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(3 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(1 year, 25 days ago) | |
Reyvow is owned by Eli Lilly And Co.
Reyvow contains Lasmiditan Succinate.
Reyvow has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Reyvow are:
- US8748459
Reyvow was authorised for market use on 31 January, 2020.
Reyvow is available in tablet;oral dosage forms.
Reyvow can be used as acute treatment of migraine.
Drug patent challenges can be filed against Reyvow from 01 February, 2024.
The generics of Reyvow are possible to be released after 05 December, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
More Information on Dosage
REYVOW family patents
